There is likely to be a sharp pick-up in interest in Australian biotechs this year as they move into their next phase of growth, which will pave the way for them to be taken over by global drug companies.

Bioscience Managers is aiming to raise $200 million for its second biotech fund that is targeting the Asia-Pacific region.